<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982121</url>
  </required_header>
  <id_info>
    <org_study_id>2017-005020-14</org_study_id>
    <secondary_id>2017/2630</secondary_id>
    <nct_id>NCT03982121</nct_id>
  </id_info>
  <brief_title>Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy</brief_title>
  <acronym>ISILI</acronym>
  <official_title>ISILI (In Situ Immunotherapy of LIver Metastases): An Openlabel, Dose-finding, Phase I Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy (FOLFOX Regimen) in Patients With Colorectal Liver Metastases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the maximum tolerated dose (MTD), the recommended phase 2 dose (RP2D) and the&#xD;
      toxicity profile (NCI CTCAE v5.0 and immune related adverse events) of i.t. administration of&#xD;
      anti-CTLA4 antibody (ipilimumab) and TLR4 agonist (synthetic glucopyranosyl lipid A&#xD;
      formulated in a stable emulsion [GLA-SE]) in colorectal LM (CRLM) in combination with&#xD;
      intravenous (i.v.) administration of anti-PD-1 antibody (nivolumab) and chemotherapy (FOLFOX&#xD;
      regimen).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never began because of withdrawal of the industrial partner&#xD;
  </why_stopped>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Actual">February 12, 2020</completion_date>
  <primary_completion_date type="Actual">February 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter, open-label, dose-escalation combination phase 1 study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>For all the cohorts, the DLT period to determine the MTD will be 28 days</time_frame>
    <description>MTD will be determined based on the DLT definitions and identified as the maximum dose level at which less than 33% of DLT are observed in the evaluable patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommanded phase 2 dose (RP2D)</measure>
    <time_frame>RP2D will be assessed on 8 weeks</time_frame>
    <description>RP2D will be determined based on the MTD identified, on analysis of DLT defining events</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX IV + NIVOLUMAB IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX IV + GLA IT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX IV + IPILIMUMAB IT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX IV + NIVOLUMAB IV + GLA IT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX IV + NIVOLUMAB IV + IPILIMUMAB IT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LFOX IV + NIVOLUMAB IV + GLA IT + IPILIMUMAB IT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
    <description>Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 240 mg</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab 5 or 10 or 25 mg</description>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLA-SE</intervention_name>
    <description>GLA-SE 1 or 2 or 5 or 10 or 20 μg</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed colorectal adenocarcinoma.&#xD;
&#xD;
          2. At least one CRLM&#xD;
&#xD;
               -  measurable according to RECIST 1.1,&#xD;
&#xD;
               -  at least &gt;2 cm in maximal diameter,&#xD;
&#xD;
               -  visible on non-contrast enhanced computerized tomography (CT) scan or&#xD;
                  ultrasonography,&#xD;
&#xD;
               -  amenable to biopsy,&#xD;
&#xD;
               -  and amenable to percutaneous i.t. injection.&#xD;
&#xD;
          3. At least one other metastasis (controlateral CRLM or a distant visceral or lymph node&#xD;
             metastasis)&#xD;
&#xD;
               -  measurable according to RECIST 1.1,&#xD;
&#xD;
               -  and amenable to biopsy.&#xD;
&#xD;
          4. Tumor lesions located in previously irradiated areas are considered measurable if&#xD;
             disease progression has been demonstrated in such lesions.&#xD;
&#xD;
          5. Tumor liver involvement &lt;50% on baseline CT scan.&#xD;
&#xD;
          6. Previous failure of active drug classes in mCRC (fluoropyrimidines, oxaliplatin,&#xD;
             irinotecan, EGFR inhibitors [if wild-type RAS mCRC] and antiangiogenics).&#xD;
&#xD;
          7. Representative tumor specimens at the initial diagnosis of CRC (paraffin blocks&#xD;
             (preferred) or at least 10 unstained slides), with the corresponding pathology report,&#xD;
             if available.&#xD;
&#xD;
          8. Age &gt;/=18 years.&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1&#xD;
&#xD;
         10. Expected life expectancy &gt;3 months (no rapidly progressive disease).&#xD;
&#xD;
         11. Adequate organ functions:&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL or ≥5.6 mmol/L (blood cell transfusions are allowed), absolute&#xD;
                  neutrophil count (ANC) ≥1.5 x 109/L, platelets ≥100 x 109/L&#xD;
&#xD;
               -  Serum creatinine ≤1.5 X upper limit of normal (ULN) or creatinine clearance&#xD;
                  (measured, or calculated per institutional standard) ≥50 mL/min for subject with&#xD;
                  creatinine levels &gt;1.5 x institutional ULN (glomerular filtration rate can also&#xD;
                  be used in place of creatinine or creatinine clearance)&#xD;
&#xD;
               -  Serum total bilirubin ≤1.5 ULN or direct (unconjugated) bilirubin ≤ULN for&#xD;
                  subjects with total bilirubin levels &gt;1.5 ULN&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) ≤5 ULN&#xD;
&#xD;
               -  Albumin &gt;33 g/L&#xD;
&#xD;
               -  International normalized ratio (INR) or prothrombin time (PT) ≤1.5 ULN unless&#xD;
                  subject is receiving anticoagulant therapy as long as PT or activated partial&#xD;
                  thromboplastin time (aPTT) is within therapeutic range of intended use of&#xD;
                  anticoagulants&#xD;
&#xD;
         12. Female subjects of childbearing potential should have a negative urine or serum&#xD;
             pregnancy test within 24 hours prior to receiving the first dose of study medication.&#xD;
             If the urine test is positive or cannot be confirmed as negative, a serum pregnancy&#xD;
             test will be required.&#xD;
&#xD;
         13. Female subjects of childbearing potential should be willing to use two validated&#xD;
             methods of birth control or be surgically sterile, or abstain from heterosexual&#xD;
             activity for the course of the study through 7 months after the last dose of study&#xD;
             medication (Reference Section 5.9.2). Subjects of childbearing potential are those who&#xD;
             have not been surgically sterilized or have not been free from menses for &gt; 1 year.&#xD;
&#xD;
         14. Sexually active male subjects unless surgically sterile, must agree to use condoms as&#xD;
             an effective barrier method of contraception or abstain from heterosexual activity for&#xD;
             the course of the study through 7 months after the last dose of study medication. It&#xD;
             is recommended that their sexual partners use an effective contraceptive during the&#xD;
             same period.&#xD;
&#xD;
         15. Signed informed consent.&#xD;
&#xD;
         16. Affiliation to or beneficiary of a social security system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy or contraindication to oxaliplatin (including peripheral neuropathy [≥ grade&#xD;
             2]), fluorouracil (including known dihydropyrimidine dehydrogenase (DPD) deficiency)&#xD;
             or leucovorin or to any other study drug.&#xD;
&#xD;
          2. Prior history of intolerance to full-dose FOLFOX regimen.&#xD;
&#xD;
          3. History of anterior organ transplantation, including allograft stem cell&#xD;
             transplantation&#xD;
&#xD;
          4. History of interstitial lung disease&#xD;
&#xD;
          5. Patients eligible for curative-intent local therapies (e.g., surgery or&#xD;
             thermablation).&#xD;
&#xD;
          6. Contraindication to percutaneous injection/biopsy (e.g., coagulation disorder,&#xD;
             anticoagulant or antiaggregant therapy). Patients treated with low molecular weight&#xD;
             heparin (LMWH) are eligible if they can interrupt their treatment for biopsies and&#xD;
             i.t. injections.&#xD;
&#xD;
          7. Concomitant administration of any other anticancer therapy during the trial treatment&#xD;
             period.&#xD;
&#xD;
          8. Prior chemotherapy, targeted therapy or radiation therapy within 2 weeks prior to&#xD;
             study Day 1 or adverse events due to a previously administered agent that have not&#xD;
             recovered (i.e., ≤ Grade 1) at baseline.&#xD;
&#xD;
          9. Immunodeficiency or systemic steroid therapy equivalent to prednisolone &gt;10mg/day or&#xD;
             any other form of immunosuppressive therapy within 7 days prior to the first dose of&#xD;
             trial treatment.&#xD;
&#xD;
         10. Other malignancy within 2 years prior to enrollment with the exception of curatively&#xD;
             treated basal-cell carcinoma of the skin, squamous-cell carcinoma of the skin, and/or&#xD;
             curatively resected in situ cervical and/or in situ breast cancers.&#xD;
&#xD;
         11. Symptomatic active central nervous system metastases and/or carcinomatous meningitis.&#xD;
&#xD;
         12. Active automimmune disease requiring systemic treatment within the past 3 months or a&#xD;
             documented history of clinically severe autoimmune disease, or a syndrome that&#xD;
             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or&#xD;
             asymptomatic asthma/atopy under topical/aerosol therapies would be an exception to&#xD;
             this rule. Subjects who require intermittent use of bronchodilators or local steroid&#xD;
             injections would not be excluded from the study. Subjects with stable hypothyroidism&#xD;
             on hormone replacement or Sjogren's syndrome will not be excluded from the study.&#xD;
             Patients with controlled type 1diabetes mellitus on a stable insulin regimen may be&#xD;
             eligible for this study.&#xD;
&#xD;
         13. Active infection requiring systemic therapy.&#xD;
&#xD;
         14. Pregnancy or breastfeeding, or inadequate contraceptive method, or expectation to&#xD;
             conceive children within the projected duration of the trial, starting with the&#xD;
             pre-screening or screening visit through 7 months after the last dose of trial&#xD;
             treatment.&#xD;
&#xD;
         15. Prior immunotherapy, including anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or&#xD;
             anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibodies (including&#xD;
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation&#xD;
             or checkpoint pathways).&#xD;
&#xD;
         16. Clinically significant liver disease (i.e., with clinical, biological or morphological&#xD;
             signs or symptoms of liver dysfunction, such as jaundice, hepatic encephalopathy,&#xD;
             non-malignant ascites, radiological/endoscopic evidence of portal hypertension,&#xD;
             biological evidence of liver insufficiency, etc.), including active viral, alcoholic,&#xD;
             or other hepatitis, cirrhosis, severe oxaliplatin-induced sinusoidal obstruction&#xD;
             syndrome (SOS) and inherited liver disease.&#xD;
&#xD;
         17. Known active Hepatitis B virus infection (e.g., HBsAg reactive) or Hepatitis C virus&#xD;
             infection (e.g., HCV RNA [qualitative] is detected) and positive Hepatitis test&#xD;
             results.&#xD;
&#xD;
         18. Known history of Human Immunodeficiency Virus (HIV) (HIV 1 and 2 antibodies) and&#xD;
             positive HIV test results.&#xD;
&#xD;
         19. Administration of a live vaccine within 30 days prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
         20. Any physical, psychological or social condition/reason that would preclude adequate&#xD;
             follow-up or hamper patient's safety according to the investigator's opinion.&#xD;
&#xD;
         21. Patient under guardianship or deprived of his liberty by a judicial or administrative&#xD;
             decision or incapable of giving its consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

